Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma
AH Neufeld - Brain research bulletin, 2004 - Elsevier
Excessive nitric oxide, generated by inducible NOS-2 in astrocytes and microglia in the optic
nerve head of patients with glaucoma, may contribute to the optic neuropathy associated
with the disease. A rat model of glaucoma, in which there is chronic, moderately elevated
IOP and slow loss of retinal ganglion cells, has been established to study pharmacological
agents that have the potential to be neuroprotective. In this model, the pharmacological use
of an inhibitor of NOS-2, aminoguanidine, significantly prevents the loss of retinal ganglion …
nerve head of patients with glaucoma, may contribute to the optic neuropathy associated
with the disease. A rat model of glaucoma, in which there is chronic, moderately elevated
IOP and slow loss of retinal ganglion cells, has been established to study pharmacological
agents that have the potential to be neuroprotective. In this model, the pharmacological use
of an inhibitor of NOS-2, aminoguanidine, significantly prevents the loss of retinal ganglion …